Bone marrow disease in rhabdomyosarcoma visualized by 2-[

Bone marrow metastases Flurodeoxyglucose F18 Pediatrics Positron emission tomography computed tomography Rhabdomyosarcoma

Journal

Pediatric radiology
ISSN: 1432-1998
Titre abrégé: Pediatr Radiol
Pays: Germany
ID NLM: 0365332

Informations de publication

Date de publication:
26 Apr 2024
Historique:
received: 17 12 2023
accepted: 15 04 2024
revised: 12 04 2024
medline: 27 4 2024
pubmed: 27 4 2024
entrez: 26 4 2024
Statut: aheadofprint

Résumé

Bone marrow metastases-noted in 6% of patients with rhabdomyosarcoma-have been linked to very poor outcomes. Bilateral bone marrow sampling from iliac crests has been the gold standard for bone marrow examination in rhabdomyosarcoma, but sampling errors due to patchy bone marrow involvement may limit its sensitivity. Here, we report the case of a 6-year-old boy with embryonal rhabdomyosarcoma of the skull base and multiple 2-[

Identifiants

pubmed: 38671145
doi: 10.1007/s00247-024-05933-5
pii: 10.1007/s00247-024-05933-5
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2024. The Author(s).

Références

Hettmer S, Linardic CM, Kelsey A et al (2022) Molecular testing of rhabdomyosarcoma in clinical trials to improve risk stratification and outcome: a consensus view from European paediatric soft tissue sarcoma Study Group, Children’s Oncology Group and Cooperative Weichteilsarkom-Studiengruppe. Eur J Cancer 172:367–386. https://doi.org/10.1016/j.ejca.2022.05.036
doi: 10.1016/j.ejca.2022.05.036 pubmed: 35839732
Bailey KA, Wexler LH (2020) Pediatric rhabdomyosarcoma with bone marrow metastasis. Pediatr Blood Cancer 67:e28219. https://doi.org/10.1002/pbc.28219
doi: 10.1002/pbc.28219 pubmed: 32100935 pmcid: 7643423
Schoot RA, van Ewijk R, von Witzleben AA et al (2023) INternational soft tissue saRcoma ConsorTium (INSTRuCT) consensus statement: imaging recommendations for the management of rhabdomyosarcoma. Eur J Radiol 166:111012. https://doi.org/10.1016/j.ejrad.2023.111012
doi: 10.1016/j.ejrad.2023.111012 pubmed: 37541182
Federico SM, Spunt SL, Krasin MJ et al (2012) Comparison of PET-CT and conventional imaging in staging pediatric rhabdomyosarcoma. Pediatr Blood Cancer 60:1128–1134. https://doi.org/10.1002/pbc.24430
doi: 10.1002/pbc.24430 pubmed: 23255260 pmcid: 4266929
Vaarwerk B, Breunis WB, Haveman LM et al (2021) Fluorine-18-fluorodeoxyglucose (FDG) positron emission tomography (PET) computed tomography (CT) for the detection of bone, lung, and lymph node metastases in rhabdomyosarcoma. Cochrane Database Syst Rev 11:CD012325. https://doi.org/10.1002/14651858.CD012325.pub2
doi: 10.1002/14651858.CD012325.pub2 pubmed: 34753195
Volker T, Denecke T, Steffen I et al (2007) Positron emission tomography for staging of pediatric sarcoma patients: results of a prospective multicenter trial. J Clin Oncol 25:5435–5441. https://doi.org/10.1200/JCO.2007.12.2473
doi: 10.1200/JCO.2007.12.2473 pubmed: 18048826
Weiss AR, Lyden ER, Anderson JR et al (2013) Histologic and clinical characteristics can guide staging evaluations for children and adolescents with rhabdomyosarcoma: a report from the Children’s Oncology Group Soft Tissue Sarcoma Committee. J Clin Oncol 3:3226–3232. https://doi.org/10.1200/JCO.2012.44.6476
doi: 10.1200/JCO.2012.44.6476
Mercolini F, Zucchetta P, Jehanno N et al (2021) Role of (18)F-FDG-PET/CT in the staging of metastatic rhabdomyosarcoma: a report from the European paediatric soft tissue sarcoma Study Group. Eur J Cancer 155:155–162. https://doi.org/10.1016/j.ejca.2021.07.006
doi: 10.1016/j.ejca.2021.07.006 pubmed: 34385068

Auteurs

Pia Kröning (P)

Division of General Pediatrics, Department of Pediatric and Adolescent Medicine, University Medical Center Freiburg, University of Freiburg, Freiburg, Germany.

Sebastian Berg (S)

Division of Pediatric Radiology, Department of Radiology, University Medical Center Freiburg, University of Freiburg, Freiburg, Germany.

Martin T Freitag (MT)

Department of Nuclear Medicine, University Medical Center Freiburg, University of Freiburg, Freiburg, Germany.

Reineke A Schoot (RA)

Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.

Alexandra Fischer (A)

Division of Pediatric Hematology and Oncology, Department of Pediatric and Adolescent Medicine, University Medical Center Freiburg, University of Freiburg, Freiburg, Germany.

Alexander Puzik (A)

Division of Pediatric Hematology and Oncology, Department of Pediatric and Adolescent Medicine, University Medical Center Freiburg, University of Freiburg, Freiburg, Germany.

T Feuchtinger (T)

Division of Pediatric Hematology and Oncology, Department of Pediatric and Adolescent Medicine, University Medical Center Freiburg, University of Freiburg, Freiburg, Germany.

Charlotte Niemeyer (C)

Division of Pediatric Hematology and Oncology, Department of Pediatric and Adolescent Medicine, University Medical Center Freiburg, University of Freiburg, Freiburg, Germany.

Philipp Tobias Meyer (PT)

Department of Nuclear Medicine, University Medical Center Freiburg, University of Freiburg, Freiburg, Germany.

Markus Uhl (M)

Division of Pediatric Radiology, Department of Radiology, University Medical Center Freiburg, University of Freiburg, Freiburg, Germany.

Simone Hettmer (S)

Division of Pediatric Hematology and Oncology, Department of Pediatric and Adolescent Medicine, University Medical Center Freiburg, University of Freiburg, Freiburg, Germany. simone.hettmer@uk-halle.de.
Universitätsmedizin Halle, Martin Luther University, Pediatrics 1, Ernst-Grube-Strasse 40, 06120, Halle (Saale), Germany. simone.hettmer@uk-halle.de.

Classifications MeSH